BioStock: BioInvent’s CMO comments on phase I/IIa data with BI-1808

BioInvent’s phase I/IIa study with first-in-class anti-TNFR2 antibody BI-1808 in advanced malignancies has produced positive results. The strong interim safety data paves the way for the phase IIa part of the study. BioStock contacted the company’s CMO Andres McAllister to learn more.

Read the interview with BioInvent's CMO Andres McAllister at biostock.se:

https://www.biostock.se/en/2023/06/bioinvents-cmo-comments-on-phase-i-iia-data-with-bi-1808/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/